0000000000423552

AUTHOR

H. Choi

showing 2 related works from this author

Search for Production of Invisible Final States in Single-Photon Decays of Υ(1S)

2010

We search for single-photon decays of the Upsilon(1S) resonance, Upsilon->gamma+invisible, where the invisible state is either a particle of definite mass, such as a light Higgs boson A0, or a pair of dark matter particles, chi chi-bar. Both A0 and chi are assumed to have zero spin. We tag Upsilon(1S) decays with a dipion transition Upsilon(2S)->pi+pi-Upsilon(1S) and look for events with a single energetic photon and significant missing energy. We find no evidence for such processes in the mass range m_A0<=9.2 GeV and m_chi<=4.5 GeV in the sample of 98e6 Upsilon(2S) decays collected with the BaBar detector and set stringent limits on new physics models that contain light dark ma…

Particle physicsPhotonAstrophysics::High Energy Astrophysical PhenomenaPhysics beyond the Standard ModelElectron–positron annihilationDark matterFOS: Physical sciencesGeneral Physics and Astronomy01 natural sciencesResonance (particle physics)High Energy Physics - ExperimentNuclear physicsHigh Energy Physics - Experiment (hep-ex)PACS: 13.20.Gd 12.60.Jv 14.80.Da 95.35.+d0103 physical sciencessingle-photon decays of Upsilon(1S)[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]010306 general physicsLight dark matterPhysicsMissing energy010308 nuclear & particles physicsParticle physicsBABAR detectorHEPBaBarHiggs bosonHigh Energy Physics::ExperimentFísica de partículesExperimentsBaBar detector at SLAC
researchProduct

TH-302 + Gemcitabine (G + T) vs Gemcitabine (G) in Patients with Previously Untreated advanced Pancreatic Cancer (PAC)

2012

ABSTRACT Background TH-302 is a hypoxia targeted prodrug with a hypoxia-triggered 2-nitroimidazole component designed to release the DNA alkylator, bromo-isophosphoramide mustard (Br-IPM), when reduced in severe hypoxia. A randomized Phase 2B study (NCT01144455) was conducted to assess the benefit of G + T to standard dose G as first-line therapy of PAC. Materials and methods An open-label multi-center study of two dose levels of TH-302 (240 mg/m2 or 340 mg/m2) in combination with G versus G alone (randomized 1:1:1). G (1000 mg/m2) and T were administered IV over 30-60 minutes on Days 1, 8 and 15 of a 28-day cycle. Patients on the G could crossover after progression and be randomized to a G…

medicine.medical_specialtyGastrointestinal tumorsPerformance statusbusiness.industryHematologySevere hypoxiaNeutropeniamedicine.diseaseRashGastroenterologyDiscontinuationNon colorectalOncologyInternal medicineToxicitymedicinemedicine.symptombusinessAnnals of Oncology
researchProduct